Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × efalizumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 1 Alopecia 1

Interventions

Rituximab 48 Cyclophosphamide 39 fludarabine phosphate 19 Vincristine 19 fludarabine 17 Etoposide 16 Bendamustine Hydrochloride 16 ibrutinib 14 Prednisone 14 Methotrexate 14 Doxorubicin 14 Cytarabine 14 Radiotherapy 13 Lenalidomide 13 Peripheral Blood Stem Cell Transplantation 12 Filgrastim 11 venetoclax 10 Dexamethasone 10 Melphalan 9 Brentuximab Vedotin 8 pembrolizumab 7 duvelisib 7 Whole-Body Irradiation 7 Tacrolimus 7 Mycophenolic Acid 7 Gemcitabine 7 Busulfan 7 Biopsy 7 blinatumomab 6 Nivolumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00746980 2016-06-14

Efalizumab in the Treatment of Alopecia, Phase II

Northwestern University

Phase 2 Withdrawn

Alopecia, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡